Literature DB >> 25979873

Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells.

Albert Lo1,2, Liang-Chuan S Wang3, Steven M Albelda2,3,4, Ellen Puré1,2,5, John Scholler5, James Monslow1, Diana Avery1, Kheng Newick3, Shaun O'Brien3, Rebecca A Evans2,5, David J Bajor5,4, Cynthia Clendenin5, Amy C Durham6, Elizabeth L Buza6, Robert H Vonderheide2,5,4, Carl H June2,5,7.   

Abstract

Malignant cells drive the generation of a desmoplastic and immunosuppressive tumor microenvironment. Cancer-associated stromal cells (CASC) are a heterogeneous population that provides both negative and positive signals for tumor cell growth and metastasis. Fibroblast activation protein (FAP) is a marker of a major subset of CASCs in virtually all carcinomas. Clinically, FAP expression serves as an independent negative prognostic factor for multiple types of human malignancies. Prior studies established that depletion of FAP(+) cells inhibits tumor growth by augmenting antitumor immunity. However, the potential for immune-independent effects on tumor growth have not been defined. Herein, we demonstrate that FAP(+) CASCs are required for maintenance of the provisional tumor stroma because depletion of these cells, by adoptive transfer of FAP-targeted chimeric antigen receptor (CAR) T cells, reduced extracellular matrix proteins and glycosaminoglycans. Adoptive transfer of FAP-CAR T cells also decreased tumor vascular density and restrained growth of desmoplastic human lung cancer xenografts and syngeneic murine pancreatic cancers in an immune-independent fashion. Adoptive transfer of FAP-CAR T cells also restrained autochthonous pancreatic cancer growth. These data distinguish the function of FAP(+) CASCs from other CASC subsets and provide support for further development of FAP(+) stromal cell-targeted therapies for the treatment of solid tumors. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25979873      PMCID: PMC4506263          DOI: 10.1158/0008-5472.CAN-14-3041

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  CTGF directs fibroblast differentiation from human mesenchymal stem/stromal cells and defines connective tissue healing in a rodent injury model.

Authors:  Chang H Lee; Bhranti Shah; Eduardo K Moioli; Jeremy J Mao
Journal:  J Clin Invest       Date:  2010-08-02       Impact factor: 14.808

2.  Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis.

Authors:  Jacky G Goetz; Susana Minguet; Inmaculada Navarro-Lérida; Juan José Lazcano; Rafael Samaniego; Enrique Calvo; Marta Tello; Teresa Osteso-Ibáñez; Teijo Pellinen; Asier Echarri; Ana Cerezo; Andres J P Klein-Szanto; Ricardo Garcia; Patricia J Keely; Paloma Sánchez-Mateos; Edna Cukierman; Miguel A Del Pozo
Journal:  Cell       Date:  2011-07-08       Impact factor: 41.582

Review 3.  Tumors as organs: complex tissues that interface with the entire organism.

Authors:  Mikala Egeblad; Elizabeth S Nakasone; Zena Werb
Journal:  Dev Cell       Date:  2010-06-15       Impact factor: 12.270

4.  Deletion of p120-catenin results in a tumor microenvironment with inflammation and cancer that establishes it as a tumor suppressor gene.

Authors:  Douglas B Stairs; Lauren J Bayne; Ben Rhoades; Maria E Vega; Todd J Waldron; Jiri Kalabis; Andres Klein-Szanto; Ju-Seog Lee; Jonathan P Katz; J Alan Diehl; Albert B Reynolds; Robert H Vonderheide; Anil K Rustgi
Journal:  Cancer Cell       Date:  2011-04-12       Impact factor: 31.743

Review 5.  Accessories to the crime: functions of cells recruited to the tumor microenvironment.

Authors:  Douglas Hanahan; Lisa M Coussens
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

6.  Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors.

Authors:  Hélène Salmon; Katarzyna Franciszkiewicz; Diane Damotte; Marie-Caroline Dieu-Nosjean; Pierre Validire; Alain Trautmann; Fathia Mami-Chouaib; Emmanuel Donnadieu
Journal:  J Clin Invest       Date:  2012-02-01       Impact factor: 14.808

7.  Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth.

Authors:  Michael Quante; Shui Ping Tu; Hiroyuki Tomita; Tamas Gonda; Sophie S W Wang; Shigeo Takashi; Gwang Ho Baik; Wataru Shibata; Bethany Diprete; Kelly S Betz; Richard Friedman; Andrea Varro; Benjamin Tycko; Timothy C Wang
Journal:  Cancer Cell       Date:  2011-02-15       Impact factor: 31.743

Review 8.  Stromal biology and therapy in pancreatic cancer.

Authors:  Albrecht Neesse; Patrick Michl; Kristopher K Frese; Christine Feig; Natalie Cook; Mike A Jacobetz; Martijn P Lolkema; Malte Buchholz; Kenneth P Olive; Thomas M Gress; David A Tuveson
Journal:  Gut       Date:  2010-10-21       Impact factor: 23.059

9.  CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.

Authors:  Gregory L Beatty; Elena G Chiorean; Matthew P Fishman; Babak Saboury; Ursina R Teitelbaum; Weijing Sun; Richard D Huhn; Wenru Song; Dongguang Li; Leslie L Sharp; Drew A Torigian; Peter J O'Dwyer; Robert H Vonderheide
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

10.  Pancreatic stellate cells radioprotect pancreatic cancer cells through β1-integrin signaling.

Authors:  Tine S Mantoni; Serena Lunardi; Osama Al-Assar; Atsushi Masamune; Thomas B Brunner
Journal:  Cancer Res       Date:  2011-05-10       Impact factor: 12.701

View more
  158 in total

1.  Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia.

Authors:  Kyoung Eun Lee; Michelle Spata; Lauren J Bayne; Elizabeth L Buza; Amy C Durham; David Allman; Robert H Vonderheide; M Celeste Simon
Journal:  Cancer Discov       Date:  2015-12-29       Impact factor: 39.397

2.  CCL5 mediates CD40-driven CD4+ T cell tumor infiltration and immunity.

Authors:  Austin P Huffman; Jeffrey H Lin; Samuel I Kim; Katelyn T Byrne; Robert H Vonderheide
Journal:  JCI Insight       Date:  2020-05-21

Review 3.  Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.

Authors:  Vishal Jindal; Ena Arora; Sorab Gupta
Journal:  Med Oncol       Date:  2018-05-05       Impact factor: 3.064

4.  Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.

Authors:  Andrew R Haas; Janos L Tanyi; Mark H O'Hara; Whitney L Gladney; Simon F Lacey; Drew A Torigian; Michael C Soulen; Lifeng Tian; Maureen McGarvey; Anne Marie Nelson; Caitlin S Farabaugh; Edmund Moon; Bruce L Levine; J Joseph Melenhorst; Gabriela Plesa; Carl H June; Steven M Albelda; Gregory L Beatty
Journal:  Mol Ther       Date:  2019-07-30       Impact factor: 11.454

5.  Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer.

Authors:  Sejin Chung; Paris Vail; Agnieszka K Witkiewicz; Erik S Knudsen
Journal:  Clin Cancer Res       Date:  2018-12-11       Impact factor: 12.531

6.  CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma.

Authors:  Timothy Chao; Emma E Furth; Robert H Vonderheide
Journal:  Cancer Immunol Res       Date:  2016-10-13       Impact factor: 11.151

7.  Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery.

Authors:  Jae W Lee; Chad A Komar; Fee Bengsch; Kathleen Graham; Gregory L Beatty
Journal:  Curr Protoc Pharmacol       Date:  2016-06-01

8.  Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma.

Authors:  M Kazim Panjwani; Jenessa B Smith; Keith Schutsky; Josephine Gnanandarajah; Colleen M O'Connor; Daniel J Powell; Nicola J Mason
Journal:  Mol Ther       Date:  2016-07-12       Impact factor: 11.454

Review 9.  Driving CARs on the uneven road of antigen heterogeneity in solid tumors.

Authors:  Nan Chen; Xiaoyu Li; Navin K Chintala; Zachary E Tano; Prasad S Adusumilli
Journal:  Curr Opin Immunol       Date:  2018-03-16       Impact factor: 7.486

Review 10.  Tumor cross-talk networks promote growth and support immune evasion in pancreatic cancer.

Authors:  Christopher J Halbrook; Marina Pasca di Magliano; Costas A Lyssiotis
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-03-15       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.